Adjunctive versus monotherapeutic treatment for schizophrenia: addressing antipsychotic side effects.
Hazra
Monica
M
Mamo
David C
DC
Remington
Gary
G
D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000191:economics / Q000627:therapeutic use; D000068180:Aripiprazole; D001480:Basal Ganglia Diseases / Q000139:chemically induced / Q000517:prevention & control; D004305:Dose-Response Relationship, Drug; D016527:Drug Costs; D004359:Drug Therapy, Combination; D006220:Haloperidol / Q000627:therapeutic use; D006801:Humans; D006966:Hyperprolactinemia / Q000139:chemically induced / Q000517:prevention & control; D010879:Piperazines; D019338:Polypharmacy; D015363:Quinolones; D012559:Schizophrenia / Q000188:drug therapy*
D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D000068180:Aripiprazole; D006220:Haloperidol